ELAVL1 and esophageal cancer: Further to verify the roles of LKB1, AMPK, ELAVL1, and LPCAT2 in the development of esophageal cancer, as well as the anti-tumor effect of angustoline in esophageal tumor model, we also utilized AMPK antibody and AMPK activator to treat the KYSE450 tumor bearing nude mice, and found that the tumor weights, relative tumor volume and tumor proliferation rate were significantly inhibited with the treatments of AMPK activator or angustoline, when compared with the non-treatment control.